Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus.

Figgett WA, Monaghan K, Ng M, Alhamdoosh M, Maraskovsky E, Wilson NJ, Hoi AY, Morand EF, Mackay F.

Clin Transl Immunology. 2019 Dec 12;8(12):e01093. doi: 10.1002/cti2.1093. eCollection 2019.

2.

Plasmacytoid dendritic cells from parent strains of the NZB/W F1 lupus mouse contribute different characteristics to autoimmune propensity.

Zhan Y, Kong I, Chopin M, Macri C, Zhang JG, Xie J, Nutt SL, O'Keeffe M, Hawkins ED, Morand EF, Lew AM.

Immunol Cell Biol. 2020 Jan 9. doi: 10.1111/imcb.12313. [Epub ahead of print]

PMID:
31916630
3.

Trial of Anifrolumab in Active Systemic Lupus Erythematosus.

Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R; TULIP-2 Trial Investigators.

N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18.

PMID:
31851795
4.

Assays for Inducing and Measuring Cell Death to Detect Macrophage Migration Inhibitory Factor (MIF) Release.

Zamani S, Morand EF, Flynn JK.

Methods Mol Biol. 2020;2080:173-183. doi: 10.1007/978-1-4939-9936-1_15.

PMID:
31745880
5.

Rare variants in non-coding regulatory regions of the genome that affect gene expression in systemic lupus erythematosus.

Jones SA, Cantsilieris S, Fan H, Cheng Q, Russ BE, Tucker EJ, Harris J, Rudloff I, Nold M, Northcott M, Dankers W, Toh AEJ, White SJ, Morand EF.

Sci Rep. 2019 Oct 28;9(1):15433. doi: 10.1038/s41598-019-51864-9.

6.

Treat-to-target Endpoint Definitions in Systemic Lupus Erythematosus: More Is Less?

Morand EF, Golder V.

J Rheumatol. 2019 Oct;46(10):1256-1258. doi: 10.3899/jrheum.190223. No abstract available.

PMID:
31575734
7.

Could GILZ Be the Answer to Glucocorticoid Toxicity in Lupus?

Flynn JK, Dankers W, Morand EF.

Front Immunol. 2019 Jul 17;10:1684. doi: 10.3389/fimmu.2019.01684. eCollection 2019. Review.

8.

Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus Erythematosus.

Nim HT, Connelly K, Vincent FB, Petitjean F, Hoi A, Koelmeyer R, Boyd SE, Morand EF.

Front Immunol. 2019 Jul 17;10:1649. doi: 10.3389/fimmu.2019.01649. eCollection 2019.

9.

Lupus Low Disease Activity State is Associated with Reduced Direct Healthcare Costs in Patients with Systemic Lupus Erythematosus.

Yeo AL, Koelmeyer R, Kandane-Rathnayake R, Golder V, Hoi A, Huq M, Hammond E, Nab H, Nikpour M, Morand EF.

Arthritis Care Res (Hoboken). 2019 Jul 8. doi: 10.1002/acr.24023. [Epub ahead of print]

PMID:
31282076
10.

Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus.

Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Hoi AY, Harris J, Mackay F, Morand EF.

Clin Transl Immunology. 2019 Apr 21;8(4):e01047. doi: 10.1002/cti2.1047. eCollection 2019.

11.

Analysis of serum interleukin(IL)-1α, IL-1β and IL-18 in patients with systemic sclerosis.

Lin E, Vincent FB, Sahhar J, Ngian GS, Kandane-Rathnayake R, Mende R, Morand EF, Lang T, Harris J.

Clin Transl Immunology. 2019 Apr 6;8(4):e1045. doi: 10.1002/cti2.1045. eCollection 2019.

12.

Rediscovering MIF: New Tricks for an Old Cytokine.

Harris J, VanPatten S, Deen NS, Al-Abed Y, Morand EF.

Trends Immunol. 2019 May;40(5):447-462. doi: 10.1016/j.it.2019.03.002. Epub 2019 Apr 5. Review.

PMID:
30962001
13.

Serum soluble Fas and Fas ligand (FasL) in primary Sjögren's syndrome.

Vincent FB, Bubicich M, Downie-Doyle S, Mackay F, Morand EF, Rischmueller M.

Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):254-256. Epub 2019 Feb 15. No abstract available.

14.

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.

Oon S, Huq M, Golder V, Ong PX, Morand EF, Nikpour M.

Ann Rheum Dis. 2019 May;78(5):629-633. doi: 10.1136/annrheumdis-2018-214427. Epub 2019 Jan 24.

PMID:
30679152
15.

Analysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosis.

Vincent FB, Lin E, Sahhar J, Ngian GS, Kandane-Rathnayake R, Mende R, Hoi AY, Morand EF, Lang T, Harris J.

Clin Transl Immunology. 2018 Dec 6;7(12):e1042. doi: 10.1002/cti2.1042. eCollection 2018.

16.

Development of the Asia Pacific Lupus Collaboration cohort.

Kandane-Rathnayake R, Golder V, Louthrenoo W, Luo SF, Jan Wu YJ, Li Z, An Y, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, Goldblatt F, Hao Y, Zhang Z, Al-Saleh J, Khamashta M, Takeuchi T, Tanaka Y, Bae SC, Lau CS, Hoi A, Nikpour M, Morand EF.

Int J Rheum Dis. 2019 Mar;22(3):425-433. doi: 10.1111/1756-185X.13431. Epub 2018 Nov 5.

PMID:
30398013
17.

Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus.

Vincent FB, Slavin L, Hoi AY, Kitching AR, Mackay F, Harris J, Kandane-Rathnayake R, Morand EF.

Lupus Sci Med. 2018 Oct 19;5(1):e000277. doi: 10.1136/lupus-2018-000277. eCollection 2018.

18.

Response to: 'Comment on: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg.

Morand EF, Trasieva T, Berglind A, Illei G, Tummala R.

Ann Rheum Dis. 2019 Nov;78(11):e122. doi: 10.1136/annrheumdis-2018-214487. Epub 2018 Oct 29. No abstract available.

PMID:
30373881
19.

Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus.

Vincent FB, Kandane-Rathnayake R, Hoi AY, Slavin L, Godsell JD, Kitching AR, Harris J, Nelson CL, Jenkins AJ, Chrysostomou A, Hibbs ML, Kerr PG, Rischmueller M, Mackay F, Morand EF.

Lupus. 2018 Nov;27(13):2029-2040. doi: 10.1177/0961203318804885. Epub 2018 Oct 9.

PMID:
30301439
20.

GILZ-dependent modulation of mTORC1 regulates spermatogonial maintenance.

La HM, Chan AL, Legrand JMD, Rossello FJ, Gangemi CG, Papa A, Cheng Q, Morand EF, Hobbs RM.

Development. 2018 Sep 18;145(18). pii: dev165324. doi: 10.1242/dev.165324.

21.

Serum and urinary macrophage migration inhibitory factor (MIF) in primary Sjögren's syndrome.

Vincent FB, Lang T, Kandane-Rathnayake R, Downie-Doyle S, Morand EF, Rischmueller M.

Joint Bone Spine. 2019 May;86(3):393-395. doi: 10.1016/j.jbspin.2018.07.001. Epub 2018 Jul 17. No abstract available.

PMID:
30025957
22.

Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients.

Lanata CM, Nititham J, Taylor KE, Chung SA, Torgerson DG, Seldin MF, Pons-Estel BA, Tusié-Luna T, Tsao BP, Morand EF, Alarcón-Riquelme ME, Criswell LA.

PLoS One. 2018 Jun 28;13(6):e0199003. doi: 10.1371/journal.pone.0199003. eCollection 2018.

23.

Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.

Mende R, Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Lin E, Chang J, Hoi AY, Morand EF, Harris J, Lang T.

Front Immunol. 2018 Jun 7;9:1250. doi: 10.3389/fimmu.2018.01250. eCollection 2018.

24.

Effect of storage duration on cytokine stability in human serum and plasma.

Vincent FB, Nim HT, Lee JPW, Morand EF, Harris J.

Cytokine. 2019 Jan;113:453-457. doi: 10.1016/j.cyto.2018.06.009. Epub 2018 Jun 14.

PMID:
29909979
25.

Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation.

Lang T, Lee JPW, Elgass K, Pinar AA, Tate MD, Aitken EH, Fan H, Creed SJ, Deen NS, Traore DAK, Mueller I, Stanisic D, Baiwog FS, Skene C, Wilce MCJ, Mansell A, Morand EF, Harris J.

Nat Commun. 2018 Jun 8;9(1):2223. doi: 10.1038/s41467-018-04581-2.

26.

Formyl peptide receptor activation inhibits the expansion of effector T cells and synovial fibroblasts and attenuates joint injury in models of rheumatoid arthritis.

Odobasic D, Jia Y, Kao W, Fan H, Wei X, Gu R, Ngo D, Kitching AR, Holdsworth SR, Morand EF, Yang YH.

Int Immunopharmacol. 2018 Aug;61:140-149. doi: 10.1016/j.intimp.2018.05.028. Epub 2018 Jun 4.

PMID:
29879657
27.

Author Correction: Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo.

Qin CX, Finlayson SB, Al-Sharea A, Tate M, De Blasio MJ, Deo M, Rosli S, Prakoso D, Thomas CJ, Kiriazis H, Gould E, Yang YH, Morand EF, Perretti M, Murphy AJ, Du XJ, Gao XM, Ritchie RH.

Sci Rep. 2018 May 2;8(1):7185. doi: 10.1038/s41598-018-24994-9.

28.

Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus.

Connelly KL, Kandane-Rathnayake R, Huq M, Hoi A, Nikpour M, Morand EF.

Sci Rep. 2018 Feb 19;8(1):3268. doi: 10.1038/s41598-018-20203-9.

29.

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.

Morand EF, Trasieva T, Berglind A, Illei GG, Tummala R.

Ann Rheum Dis. 2018 May;77(5):706-713. doi: 10.1136/annrheumdis-2017-212504. Epub 2018 Feb 2.

30.

Systemic lupus erythematosus: Stress and the onset of SLE.

Morand EF.

Nat Rev Rheumatol. 2018 Mar;14(3):127-128. doi: 10.1038/nrrheum.2018.2. Epub 2018 Jan 25. No abstract available.

PMID:
29367692
31.

Medical student psychological distress and academic performance.

Dendle C, Baulch J, Pellicano R, Hay M, Lichtwark I, Ayoub S, Clarke DM, Morand EF, Kumar A, Leech M, Horne K.

Med Teach. 2018 Dec;40(12):1257-1263. doi: 10.1080/0142159X.2018.1427222. Epub 2018 Jan 21.

PMID:
29355074
32.

Gilz-Activin A as a Novel Signaling Axis Orchestrating Mesenchymal Stem Cell and Th17 Cell Interplay.

Luz-Crawford P, Espinosa-Carrasco G, Ipseiz N, Contreras R, Tejedor G, Medina DA, Vega-Letter AM, Ngo D, Morand EF, Pène J, Hernandez J, Jorgensen C, Djouad F.

Theranostics. 2018 Jan 1;8(3):846-859. doi: 10.7150/thno.21793. eCollection 2018.

33.

Treat to target, remission and low disease activity in SLE.

Morand EF, Mosca M.

Best Pract Res Clin Rheumatol. 2017 Jun;31(3):342-350. doi: 10.1016/j.berh.2017.09.009. Epub 2017 Oct 13. Review.

PMID:
29224676
34.

Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?

Boulos D, Koelmeyer RL, Morand EF, Hoi AY.

Lupus Sci Med. 2017 Jul 28;4(1):e000212. doi: 10.1136/lupus-2017-000212. eCollection 2017.

35.

Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo.

Qin CX, Finlayson SB, Al-Sharea A, Tate M, De Blasio MJ, Deo M, Rosli S, Prakoso D, Thomas CJ, Kiriazis H, Gould E, Yang YH, Morand EF, Perretti M, Murphy AJ, Du XJ, Gao XM, Ritchie RH.

Sci Rep. 2017 Nov 30;7(1):16615. doi: 10.1038/s41598-017-16317-1. Erratum in: Sci Rep. 2018 May 2;8(1):7185.

36.

Discordance of patient and physician health status concerns in systemic lupus erythematosus.

Golder V, Ooi JJY, Antony AS, Ko T, Morton S, Kandane-Rathnayake R, Morand EF, Hoi AY.

Lupus. 2018 Mar;27(3):501-506. doi: 10.1177/0961203317722412. Epub 2017 Aug 1.

PMID:
28764617
37.

Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study.

Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, Li ZG, Luo SF, Sockalingam S, Lau CS, Mok MY, Lateef A, Franklyn K, Morton S, Navarra ST, Zamora L, Wu YJ, Hamijoyo L, Chan M, O'Neill S, Goldblatt F, Nikpour M, Morand EF; Asia-Pacific Lupus Collaboration.

Arthritis Res Ther. 2017 Mar 20;19(1):62. doi: 10.1186/s13075-017-1256-6.

38.

The Australian Lupus Registry and Biobank: a timely initiative.

O'Neill S, Morand EF, Hoi A.

Med J Aust. 2017 Mar 20;206(5):194-195. No abstract available.

PMID:
28301780
39.

Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study.

Golder V, Huq M, Franklyn K, Calderone A, Lateef A, Lau CS, Lee ALH, Navarra STV, Godfrey T, Oon S, Hoi AYB, Morand EF, Nikpour M.

Semin Arthritis Rheum. 2017 Jun;46(6):798-803. doi: 10.1016/j.semarthrit.2017.01.007. Epub 2017 Jan 18.

PMID:
28216192
40.

Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge Gap.

Golder V, Morand EF, Hoi AY.

J Rheumatol. 2017 Mar;44(3):271-278. doi: 10.3899/jrheum.160334. Epub 2017 Jan 15. Review.

PMID:
28089979
41.

It hasn't gone away: the problem of glucocorticoid use in lupus remains.

Apostolopoulos D, Morand EF.

Rheumatology (Oxford). 2017 Apr 1;56(suppl_1):i114-i122. doi: 10.1093/rheumatology/kew406. Review.

PMID:
28013208
42.

Independent association of glucocorticoids with damage accrual in SLE.

Apostolopoulos D, Kandane-Rathnayake R, Raghunath S, Hoi A, Nikpour M, Morand EF.

Lupus Sci Med. 2016 Nov 22;3(1):e000157. eCollection 2016.

43.

Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort.

Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, Li ZG, Luo SF, Sockalingam S, Lau CS, Lee AL, Mok MY, Lateef A, Franklyn K, Morton S, Navarra ST, Zamora L, Wu YJ, Hamijoyo L, Chan M, O'Neill S, Goldblatt F, Morand EF, Nikpour M; Asia-Pacific Lupus Collaboration.

Arthritis Res Ther. 2016 Nov 9;18(1):260.

44.

Connective tissue diseases: Remission in SLE - are we there yet?

Morand EF.

Nat Rev Rheumatol. 2016 Dec;12(12):696-698. doi: 10.1038/nrrheum.2016.174. Epub 2016 Oct 27. No abstract available.

PMID:
27784893
45.

Editorial: Focus on Systemic Lupus Erythematosus.

Harris J, Morand EF.

Front Immunol. 2016 Oct 3;7:400. eCollection 2016. No abstract available.

46.

Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus.

Godsell J, Rudloff I, Kandane-Rathnayake R, Hoi A, Nold MF, Morand EF, Harris J.

Sci Rep. 2016 Oct 6;6:34604. doi: 10.1038/srep34604.

47.

Validation of the Lupus Impact Tracker in an Australian patient cohort.

Antony A, Kandane-Rathnayake RK, Ko T, Boulos D, Hoi AY, Jolly M, Morand EF.

Lupus. 2017 Jan;26(1):98-105. Epub 2016 Aug 11.

PMID:
27516435
48.

Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.

He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, Xu C, Hou Z, Leong YA, Zhu L, Feng J, An Y, Jia Y, Li C, Liu X, Ye H, Ren L, Li R, Yao H, Li Y, Chen S, Zhang X, Su Y, Guo J, Shen N, Morand EF, Yu D, Li Z.

Nat Med. 2016 Sep;22(9):991-3. doi: 10.1038/nm.4148. Epub 2016 Aug 8.

PMID:
27500725
49.

Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus.

Connelly KL, Kandane-Rathnayake R, Hoi A, Nikpour M, Morand EF.

Sci Rep. 2016 Jul 25;6:29909. doi: 10.1038/srep29909.

50.

Loss of autophagy enhances MIF/macrophage migration inhibitory factor release by macrophages.

Lee JP, Foote A, Fan H, Peral de Castro C, Lang T, Jones SA, Gavrilescu N, Mills KH, Leech M, Morand EF, Harris J.

Autophagy. 2016 Jun 2;12(6):907-16. doi: 10.1080/15548627.2016.1164358. Epub 2016 May 10.

Supplemental Content

Loading ...
Support Center